Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.

Ma RL, Deng Y, Wang YF, Zhu SY, Ding XS, Sun AJ

Chinese medical journal3 Nov 2021Cited by 47 (Europe PMC)

PMID34732660PMCIDPMC8667970DOI10.1097/cm9.0000000000001712PepBankPUB-34732660

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight or obese women with PCOS, adding exenatide to metformin reduced weight more than metformin alone.
In plain wordsIn overweight or obese women with PCOS, adding exenatide to metformin reduced weight more than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 40
Comparator
Metformin alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mg once weekly · 12 weeksAs given in this study (human).
Measurements
Weight loss
3.8 kg
exenatide plus metformin
Weight loss
2.1 kg
metformin
Source sentences
Summary
Patients in the COM group on an average lost 3.8 ± 2.4 kg compared with 2.1 ± 3.0 kg in the MET group.
4 context sentences(design, population, supporting numbers)
Summary · context
COM therapy was superior to MET monotherapy in reducing weight (P = 0.045), body mass index (BMI) (P = 0.041), and waist circumference (P = 0.023).
Summary · context
Forty (80%) patients completed the study.
Summary · context
The primary outcomes were anthropometric changes associated with obesity, and the secondary outcomes included changes in reproductive hormone levels, glucose and lipid metabolism, and C-reactive protein.
Summary · context
Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks.
Report a problemFND-3473266001
02HumanRandomized controlled trialEfficacy outcome
In overweight or obese women with PCOS, adding exenatide to metformin reduced BMI more than metformin alone.
In plain wordsIn overweight or obese women with PCOS, adding exenatide to metformin reduced BMI more than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody mass index
Study
n = 40
Comparator
Metformin alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mg once weekly · 12 weeksAs given in this study (human).
Measurements
BMI decrease
1.4 kg/m2
combination
BMI decrease
0.77 kg/m2
metformin
Source sentences
Summary
In the COM group, BMI and waist circumference decreased by 1.4 ± 0.87 kg/m2 and 4.63 ± 4.42 cm compared with 0.77 ± 1.17 kg/m2 and 1.72 ± 3.07 cm in the MET group, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
COM therapy was superior to MET monotherapy in reducing weight (P = 0.045), body mass index (BMI) (P = 0.041), and waist circumference (P = 0.023).
Summary · context
Forty (80%) patients completed the study.
Summary · context
The primary outcomes were anthropometric changes associated with obesity, and the secondary outcomes included changes in reproductive hormone levels, glucose and lipid metabolism, and C-reactive protein.
Summary · context
Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks.
Report a problemFND-3473266002
03HumanRandomized controlled trialEfficacy outcome
In overweight or obese women with PCOS, adding exenatide to metformin reduced waist circumference more than metformin alone.
In plain wordsIn overweight or obese women with PCOS, adding exenatide to metformin reduced waist circumference more than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWaist circumference
Study
n = 40
Comparator
Metformin alone
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2 mg once weekly · 12 weeksAs given in this study (human).
Measurements
Waist decrease
4.63 cm
combination
Waist decrease
1.72 cm
metformin
Source sentences
Summary
In the COM group, BMI and waist circumference decreased by 1.4 ± 0.87 kg/m2 and 4.63 ± 4.42 cm compared with 0.77 ± 1.17 kg/m2 and 1.72 ± 3.07 cm in the MET group, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
COM therapy was superior to MET monotherapy in reducing weight (P = 0.045), body mass index (BMI) (P = 0.041), and waist circumference (P = 0.023).
Summary · context
Forty (80%) patients completed the study.
Summary · context
The primary outcomes were anthropometric changes associated with obesity, and the secondary outcomes included changes in reproductive hormone levels, glucose and lipid metabolism, and C-reactive protein.
Summary · context
Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks.
Report a problemFND-3473266003
04HumanRandomized controlled trialEfficacy outcome
In women with PCOS, fasting glucose was lower with exenatide plus metformin than metformin alone.
In plain wordsIn women with PCOS, fasting glucose was lower with exenatide plus metformin than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFasting glucose
Study
n = 40
Comparator
Metformin alone
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 12 weeksAs given in this study (human).
Source sentences
Summary
Moreover, levels of fasting glucose, oral glucose tolerance test (OGTT) 2-h glucose, and OGTT 2-h insulin were significantly lower with COM therapy than with MET (P < 0.050).
3 context sentences(design, population, supporting numbers)
Summary · context
Forty (80%) patients completed the study.
Summary · context
The primary outcomes were anthropometric changes associated with obesity, and the secondary outcomes included changes in reproductive hormone levels, glucose and lipid metabolism, and C-reactive protein.
Summary · context
Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks.
Report a problemFND-3473266004
05HumanRandomized controlled trialEfficacy outcome
In women with PCOS, OGTT glucose was lower with exenatide plus metformin than metformin alone.
In plain wordsIn women with PCOS, glucose after an oral glucose test was lower with exenatide plus metformin than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseOGTT two-hour glucose
Study
n = 40
Comparator
Metformin alone
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 12 weeksAs given in this study (human).
Source sentences
Summary
Moreover, levels of fasting glucose, oral glucose tolerance test (OGTT) 2-h glucose, and OGTT 2-h insulin were significantly lower with COM therapy than with MET (P < 0.050).
3 context sentences(design, population, supporting numbers)
Summary · context
Forty (80%) patients completed the study.
Summary · context
The primary outcomes were anthropometric changes associated with obesity, and the secondary outcomes included changes in reproductive hormone levels, glucose and lipid metabolism, and C-reactive protein.
Summary · context
Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks.
Report a problemFND-3473266005
06HumanRandomized controlled trialEfficacy outcome
In women with PCOS, OGTT insulin was lower with exenatide plus metformin than metformin alone.
In plain wordsIn women with PCOS, insulin after an oral glucose test was lower with exenatide plus metformin than metformin alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseOGTT two-hour insulin
Study
n = 40
Comparator
Metformin alone
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg once weekly · 12 weeksAs given in this study (human).
Source sentences
Summary
Moreover, levels of fasting glucose, oral glucose tolerance test (OGTT) 2-h glucose, and OGTT 2-h insulin were significantly lower with COM therapy than with MET (P < 0.050).
3 context sentences(design, population, supporting numbers)
Summary · context
Forty (80%) patients completed the study.
Summary · context
The primary outcomes were anthropometric changes associated with obesity, and the secondary outcomes included changes in reproductive hormone levels, glucose and lipid metabolism, and C-reactive protein.
Summary · context
Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks.
Report a problemFND-3473266006

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialSafety outcome
In women with PCOS, mild and moderate gastrointestinal reactions were the most common adverse events with both combination therapy and metformin.
In plain wordsIn women with PCOS, mild and moderate digestive reactions were the most common adverse events with combination therapy and metformin.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedGastrointestinal reactions
Study
n: not reported in source
Comparator
Metformin alone
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Mild and moderate gastrointestinal reactions were the most common adverse events in both groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3473266007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT04029272

Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients

Peking Union Medical College Hospitaln = 80est. 20 Jul 2019 to est. 31 Dec 2020

Polycystic Ovary Syndrome

Trial page ClinicalTrials.govUpdated 23 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.